

Technology Advisory Committee C Interests Register

Topic: Teclistamab for treating relapsed and refractory multiple myeloma after 3 or more treatments (Review of TA869) [ID6333]

Publication Date: 13/11/2024

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Satish Venkateshan	TAC C Committee Member	Direct- financial	Regeneron is developing linvoseltamab a BCMAxCD3 bispecific in multiple myeloma. Satish Venkateshan works for Regeneron, pharmaceuticals/biotech company. Satish Venkateshan also owns shares in the company and has stock options.	18/05/2024	It was agreed that Satish Venkateshan's declaration would prevent him from participating in discussions on this appraisal.
Michael Chambers	TAC C Committee Member	Direct- financial	Michael Chambers has participated in an advisory panel for Pfizer in an unrelated disease area (prostate cancer) and has provided consulting advice to Sanofi in an unrelated disease area (COPD). Concluding Sept 2022. Michael Chambers supported Takeda's contributions to Innovative Medicine Initiative (IMI) projects, but this did not involve consideration of Takeda products.	17/05/2024	It was agreed that Michael Chambers' declaration would not prevent him from participating in discussions on this appraisal.

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Dr Kate Ren	TAC C Committee Member	Direct- financial	Dr Kate Ren provided statistical methodology consultancy service for a possible comparator company Pfizer for an unrelated treatment in an unrelated disease area (tofacitinib for moderate-to-severe Ulcerative Colitis).	17/05/2024 03/09/2024	It was agreed that Dr Kate Ren's declaration would not prevent her from participating in discussions on this appraisal.
Karthik Ramasamy	Clinical expert	Direct- financial Non-direct financial	Karthik Ramasamy has served as an advisor and have received speaker honoraria from Celgene (Bristol Myers Squibb), Janssen, Pfizer, Sanofi, and Takeda. Karthik Ramasamy has received conference Travel grants from Takeda and Janssen. Karthik Ramasamy has received research Grants to her institution from Takeda and BMS. Karthik Ramasamy is an Executive Member of UK Myeloma Society and Trustee for a myeloma charity. Karthik Ramasamy's nominating organisation, the UK Myeloma Society, has received educational grants from Accord, Celgene (Bristol	20/03/2024 03/09/2024	It was agreed that Karthik Ramasamy's declaration would not prevent him from providing expert advice to the committee.

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			Myers Squibb), Janssen, Pfizer, Sanofi and Takeda.		
Rakesh Popat	Clinical expert	Direct- financial	<p>Rakesh Popat is the PI for clinical trials that are sponsored by Johnson & Johnson Innovative Medicine.</p> <p>Rakesh Popat has received fees from Johnson & Johnson Innovative Medicine for speaking and consultancy advice.</p> <p>Rakesh Popat has received speaker and consultancy fees from comparator companies BMS, Pfizer and Sanofi, all unrelated to this product.</p> <p>Rakesh Popat has received research funding from Pfizer.</p> <p>Rakesh Popat is on the executive board of the UK Myeloma Society</p>	12/12/2023 03/09/2024	It was agreed that Rakesh Popat's declaration would not prevent him from providing expert advice to the committee.
Caroline Donoghue	Patient expert	Non-direct financial	Caroline Donoghue's nominating organisation, Myeloma UK, has received funding from Johnson & Johnson Innovative Medicine in the	12/12/2023	It was agreed that Caroline Donoghue's declaration would not prevent her from

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			past 12 months. Myeloma UK has previously received funding from comparator companies Celgene, BMS, Pfizer, Sanofi and Takeda.		providing expert advice to the committee.
Pedro Saramago Goncalves	TAC C Committee Member	Indirect - financial	Dr Goncalves has carried out health economics consulting in an advisory capacity for accord healthcare in an unrelated disease area (lung cancer.)	03/09/2024	It was agreed that Dr Goncalves declaration would not prevent him from participating in discussions on this appraisal.
Elizabeth Thurgar	TAC C Committee Member	Direct - financial	Elizabeth Thurgar is currently working with JNJ Netherlands on teclistamab for multiple myeloma.	03/09/2024	It was agreed that Elizabeth Thurgar's declaration would prevent her from participating in discussions on this appraisal.